Optimizing post-transplantation cell therapies to enhance graft-versus-leukemia effects in hematological malignancies
Curr Opin Immunol. 2025 Oct 10;97:102675. doi: 10.1016/j.coi.2025.102675. Online ahead of print. ABSTRACT Allogeneic hematopoietic cell transplantation (HCT) can cure patients with high-risk hematologic malignancies. Donor T and natural killer (NK) cells contribute to graft-versus-leukemia (GVL) effects that provide relapse protection. Post-HCT relapses often represent inadequate GVL, but alloreactive lymphocytes that confer GVL may also … Read more